SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial.

@article{Harada2017SR16234AN,
  title={SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial.},
  author={Tasuku Harada and I. Ohta and Yusuke Endo and Hiroshi Sunada and Hisashi Noma and Fuminori Taniguchi},
  journal={Yonago acta medica},
  year={2017},
  volume={60 4},
  pages={
          227-233
        }
}
Background SR-16234 is a selective estrogen receptor modulator (SERM) structurally different from approved SERM and has been reported to have estrogen receptor (ER) α antagonistic activity and strong affinity with a weak partial agonistic activity to ERβ receptor. SR-16234 showed strong inhibitory effects on transplanted endometrial cysts in the endometriosis model of rat and mouse. In this clinical trial, efficacy and safety of SR-16234 have been evaluated in endometriosis patients. Methods… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES